SELECTED PRESENTATIONS1. World Health Organization: Geneva, Switzerland, 1990. Immune-enhancing activities of 7,8-disubstituted guanine ribonucleoside structural analogues: relevance to vaccines forcommunicable diseases.2. Sandoz Pharmaceuticals Ltd: Basel, Switzerland, 1995. Application of selectively B-cellimmuno-suppressive substituted guanine nucleoside analogues to treatment of chronic graftversus-hostdisease.3. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1992. Clinicalapplications and mechanism of action of Loxoribine.4. Johnson & Johnson Biosciences Advisory Committee: La Jolla, CA., 1991.Immimobiological activity of the class of substituted guanine ribonucleosides.5. Ortho Pharmaceutical Corp.: Raritan, NJ., 1990. Recent developments in the synthesis andactivity of substituted guanine ribonucleosides.6. Federation of the American Societies for Experimental Biology: New Orleans, LA, 1990. C-Kinase independent restoration of specific immune responsiveness in common variableimmunodeficiency.7. La Jolla Pharmaceuticals: La Jolla, CA. 1991. Substituted guanine nucleosides andautoimmunity.8. Ortho Pharmaceutical Corp.: Toronto, Ontario. 1991. New synthetic structures and backbonesfor oligomeric polynucleotides containing substituted guanine bases: effects onimmunoenhancing activity.9. AIDS research and human retroviruses: Washington, D.C., 1993. Loxoribine: a disubstitutedguanosine with adjuvant activity.10. The Scripps Clinic, Department of Allergy and Immunology: La Jolla, CA., 1994.Immunobiological activities of Loxoribine.11. Federation of the American Societies for Experimental Biology: Anaheim, CA, 1994.Induction of CLL B cell activation and sensitivity to cycle-active cytotoxic agents.12. The Scripps Research Institute, Department of Immunology Retreat: Rancho Valencia, CA.1994. B lymphocyte signaling and stimulation.13. John Wayne Cancer Institute, Santa Monica, CA, 1995: Heightened efficacy of cancer vaccinesin combination with 7,8-disubstituted guanine ribonucleoside structural analogues.14. 9th International Congress of Immunology: San Francisco, CA., 1995. Role of cytokines inNK cell and proliferative responses to Loxoribine.15. Federation of the American Societies for Experimental Biology: Boston, MA, 1995.Intracellular nucleoside-binding proteins with specificity for loxoribine.16. The Scripps Research Institute, La Jolla, CA. 1995: Hematology/<strong>Oncology</strong> Fellows lecture.17. Genzyme Corp: Boston, MA, 1995. Immunological activities of 7,8-disubstituted guanineribonucleoside structural analogues.18. St. John's Lutheran Hospital, Libby, MT. 1997. Significance of serologic tumor markers inbreast cancer.19. Kalispell Regional Medical Center, Kalispell, MT. 1998. Nursing CME lecture: Update on20
new and developing treatments for Chronic Lymphocytic Leukemia.20. St. Joseph's Hospital, Poison, MT. 1999. Recent developments in the diagnosis and treatmentof Chronic Lymphocytic Leukemia.21. Kalispell Regional Medical Center, Kalispell, MT. 2007. Breast Cancer AwarenessSymposium: New developments in biologic treatments for breast cancer patients.22. Kalispell Regional Medical Center, Kalispell, MT. 2008. Update and discussion of multiplemyeloma.21
- Page 1 and 2: CURRICULUM VITAEMichael Gordon Good
- Page 3 and 4: Diplomate, American Board of Intern
- Page 5 and 6: 3. Immunophenotypic and Functional
- Page 7 and 8: (continued)11. Goodman, M.G., and W
- Page 9 and 10: 12. Goodman, M.G. and W.O. Weigle.
- Page 11 and 12: esistance to metabolic processing b
- Page 13 and 14: L.F. Thompson and R.W.E. Watts, eds
- Page 15 and 16: 83. Goodman, M. G., S. Wormsley, J.
- Page 17 and 18: 11. Goodman, M.G. and W.O. Weigle.
- Page 19: McKee, D, Earth, N, Guthiel, J. Com
Change language